Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Preclinical in vivo proof-of-concept for cyclic oligopeptide rescuers of pathogenic protein misfolding and aggregation associated with neurodegeneration

Project description

Innovative concept for neurodegenerative diseases

Genetically engineered bacteria have been developed as a living discovery platform for short cyclic peptides that rescue pathogenic protein misfolding and aggregation. These peptides hold promise for addressing human diseases, such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), potentially leading to new drug discoveries. The ERC-funded PoC4ProMis project aims to demonstrate in vivo proof-of-concept for potential ALS treatments by developing a method to deliver cyclic peptides to the central nervous system and testing these molecules in established ALS mouse models. Furthermore, the project will pursue further patent protection for the peptides with the goal of proposing promising new drugs and delivery formulations for neurodegenerative diseases of high medicinal and commercial value.

Objective

Within the ERC Consolidator Grant ProMiDis, my team and I have developed genetically engineered bacteria that function as a stand-alone, living discovery platform for short, drug-like cyclic peptides rescuing the misfolding and aggregation of proteins associated with human diseases (protein misfolding diseases, PMDs). By applying this technology, we have discovered hundreds of new molecules-putative drugs against notorious PMDs, such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). We have filed patent applications for aspects of this technology and for the first set of bioactive molecules. In PoC4ProMis, we will demonstrate in vivo proof-of-concept for the most promising molecules targeting the devastating neurodegenerative disease ALS. To achieve this, we will first develop an optimized method for efficient delivery of cyclic peptides to the central nervous system (CNS) by utilizing a novel specialized CNS delivery vehicle. Then, we will evaluate the effectiveness of our lead molecules to reverse disease phenotypes in well-established ALS mouse models. Finally, we will explore opportunities to strengthen further our IP portfolio by patent-protecting our SOD1-targeting cyclic peptides with additional claims relating to method-of-use and mode of delivery. PoC4ProMis will demonstrate in vivo PoC and will provide a general approach for efficient CNS delivery of cyclic peptide drugs targeting additional neurodegenerative diseases of high priority for drug development.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

RESQ BIOTECH IDIOTIKI KEFALAIOUCHIKI ETAIREIA
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Address
EPISTIMONIKO PARKO PATRON 0 RIOU/ACHAIAS
26 500 PATRA
Greece

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Κεντρική Ελλάδα Δυτική Ελλάδα Αχαΐα
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0